Helix Biosciences
HealthcareSeries CRisk Assessment
Helix Biosciences has experienced a 58% headcount collapse — the most severe workforce decline in the portfolio. Combined with deteriorating Glassdoor sentiment and no hiring activity, this pattern closely mirrors early-stage signals observed in Convoy and Olive AI before their shutdowns.
Signal Dimensions
Peak HC
89
Current HC
37
HC Decline
-58%
Open Roles
0
58% headcount reduction with zero open roles. This is the most severe workforce signal in the portfolio.
Last Raise
Series C
Time Since Raise
14 months
Funding Stage
Growth
Burn Indicator
High
14 months since Series C with severe headcount cuts — suggests runway pressure or strategic pivot under duress.
GD Rating
3.9
CEO Approval
64%
Business Outlook
53%
Review Trend
Declining
Sentiment declining but not yet critical. Glassdoor rating holding above 3.5 — may lag workforce reality.
Competitor Raises
3
SoV Trend
Declining
Talent Outflow
Moderate
Sector Growth
8%
Competitors raising in an active sector while Helix contracts. Talent outflow to competitors is a concern.
Articles (12mo)
5
Avg Tone
-0.4
Days w/ Coverage
4
Sentiment
Neutral
Minimal media presence. Company not yet in active news cycle.
Last Filing
Dec 2025
Auditor Changes
0
Director Changes
0
Overdue Filings
0
Filings current. No anomalies detected.
Score Drivers
Workforce collapse
Funding pressure
Sentiment decline
Market position erosion
Confidence: HIGH · 6 of 6 signals active · Based on 2 matching failure patterns · Typical lead time: 14 months
Recommended Actions
IMMEDIATE — This Week
NEXT 30 DAYS
RISK IF UNCHANGED